AI Market Mood: Stock Dashboard
XAIR
Fundamental
Company: Beyond Air Inc
Sector: Healthcare
Industry: Medical Devices
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -7.53
Insider Own: 5.81%
Shs Outstand: 8.01M
Perf Week: -17.34%
Market Cap: 11.45M
Forward P/E: -
EPS next Y: -2.07
Insider Trans: 1.31%
Shs Float: 7.54M
Perf Month: -44.57%
Enterprise Value: 12.75M
PEG: -
EPS next Q: -0.69
Inst Own: 7.85%
Short Float: 1.61%
Perf Quarter: -38.36%
Income: -36.70M
P/S: 1.97
EPS this Y: 73.13%
Inst Trans: -8.63%
Short Ratio: 0.04
Perf Half Y: -60.14%
Sales: 5.80M
P/B: 0.90
EPS next Y Percentage: 44.17%
ROA: -87.40%
Short Interest: 0.12M
Perf YTD: -80.06%
Book/sh: 1.59
P/C: 1.05
EPS next 5Y: 74.09%
ROE: -179.63%
52W High: 13.52 -89.42%
Perf Year: -85.98%
Cash/sh: 1.36
P/FCF: -
EPS past 3/5Y: 25.75% 17.29%
ROIC: -152.16%
52W Low: 1.36 5.15%
Perf 3Y: -98.91%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - 21.66%
Gross Margin: -6.69%
Volatility W: 8.81%
Volatility M: 9.14%
Perf 5Y: -98.71%
Dividend TTM: -
EV/Sales: 2.20
EPS Y/Y TTM: 73.23%
Oper. Margin: -575.72%
ATR (14): 0.18
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 3.73
Sales Y/Y TTM: 147.74%
Profit Margin: -632.51%
RSI (14): 25.93
Recom: 1.50
Dividend Gr. 3/5Y: - -
Current Ratio: 4.24
EPS Q/Q: 77.97%
SMA20: -26.69%
Beta: 0.34
Target Price: 10.33
Payout: -
Debt/Eq: 0.93
Sales Q/Q: 127.82%
SMA50: -36.67%
Rel Volume: 0.07
Prev Close: 1.47
Employees: 61
LT Debt/Eq: 0.89
Earnings: Nov 10 AMC
SMA200: -62.69%
Avg Volume: 3.19M
Price: 1.43
IPO: Sep 23, 2016
Option/Short: No / Yes
EPS/Sales Surpr.: -61.64% -15.27%
Trades:
Volume: 213,394
Change: -2.39%
Technical:
Latest News:
New AI drug discovery powerhouse Xaira rises with $1B in funding - Fierce Biotech very bullish
XAIR
Summary: Xaira Therapeutics has emerged with $1 billion in committed funding and an impressive team led by prominent figures in the biotech industry, including Marc Tessier-Lavigne, Ph.D., and David Baker, Ph.D. The company aims to revolutionize drug discovery by combining machine learning, data generation, and therapeutic product development.
Full article2024-04-24T14:00:06Z